Top

Published in:

Open Access 01-06-2020 | Insulins | Original Article

Approved LXR agonists exert unspecific effects on pancreatic β-cell function

Authors: Jonas Maczewsky, Julia Kaiser, Peter Krippeit-Drews, Gisela Drews

Published in: Endocrine | Issue 3/2020

Abstract

Novel agonists of the nuclear liver-X-receptor (LXR) are designed to treat metabolic disorders or cancer. The rationale to develop these new drugs is based on promising results with established LXR agonist like T0901317 and GW3965. LXRα and LXRβ are expressed in β-cells, and expression is increased by T0901317. The aim of the present study was to evaluate whether effects of these drugs on β-cell function are specific and reliably linked to LXR activation. T0901317 and GW3965, widely used as specific LXR agonists, show rapid, non-genomic effects on stimulus-secretion coupling of mouse pancreatic β-cells at low µM concentrations. T0901317 lowered the cytosolic Ca²⁺ concentration, reduced or completely inhibited action potentials, and decreased insulin secretion. GW3965 exerted similar effects on insulin secretion. T0901317 affected the production of reactive oxygen species and ATP. The involvement of the classical nuclear LXRs in T0901317- and GW3965-mediated effects in β-cells could be ruled out using LXRα, LXRβ and double knockout mice. Our results strongly suggest that LXR agonists, that are considered to be specific for this receptor, interfere with mitochondrial metabolism and metabolism-independent processes in β-cells. Thus, it is indispensable to test novel LXR agonists accompanying to ongoing clinical trials for acute and chronic effects on cell function in cellular systems and/or animal models lacking classical LXRs.

D.J. Peet, S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E. Hammer, D.J. Mangelsdorf, Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93(5), 693–704 (1998)CrossRefPubMed

B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, D.J. Mangelsdorf, An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383(6602), 728–731 (1996). https://doi.org/10.1038/383728a0 CrossRefPubMed

D.J. Peet, B.A. Janowski, D.J. Mangelsdorf, The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8(5), 571–575 (1998). https://doi.org/10.1016/s0959-437x(98)80013-0 CrossRefPubMed

K.R. Steffensen, J.A. Gustafsson, Putative metabolic effects of the liver X receptor (LXR). Diabetes 53(Suppl 1), S36–S42 (2004)CrossRefPubMed

S. Ferderbar, E.C. Pereira, E. Apolinario, M.C. Bertolami, A. Faludi, O. Monte, L.E. Calliari, J.E. Sales, A.R. Gagliardi, H.T. Xavier, D.S. Abdalla, Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 23(1), 35–42 (2007). https://doi.org/10.1002/dmrr.645 CrossRefPubMed

L. Chang, Z. Zhang, W. Li, J. Dai, Y. Guan, X. Wang, Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-kappaB pathway. Biochem. Biophys. Res. Commun. 357(3), 772–778 (2007). https://doi.org/10.1016/j.bbrc.2007.04.016 CrossRefPubMed

Q. He, J. Pu, A. Yuan, W.B. Lau, E. Gao, W.J. Koch, X.L. Ma, B. He, Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia/reperfusion injury. Circ. Heart Fail. 7(6), 1032–1041 (2014). https://doi.org/10.1161/CIRCHEARTFAILURE.114.001260 CrossRefPubMedPubMedCentral

Q. He, J. Pu, A. Yuan, T. Yao, X. Ying, Y. Zhao, L. Xu, H. Tong, B. He, Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice. Cardiovascular Diabetol. 13(1), 149 (2014). https://doi.org/10.1186/s12933-014-0149-0 CrossRef

Y. Dong, G. Gao, H. Fan, S. Li, X. Li, W. Liu, Activation of the liver X receptor by agonist TO901317 improves hepatic insulin resistance via suppressing reactive oxygen species and JNK pathway. PLoS ONE 10(4), e0124778 (2015). https://doi.org/10.1371/journal.pone.0124778 CrossRefPubMedPubMedCentral

10.

M. Baranowski, P. Zabielski, A.U. Blachnio-Zabielska, E. Harasim, A. Chabowski, J. Gorski, Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation. Cell Physiol. Biochem. 33(4), 1047–1057 (2014). https://doi.org/10.1159/000358675 CrossRefPubMed

11.

B.A. Laffitte, L.C. Chao, J. Li, R. Walczak, S. Hummasti, S.B. Joseph, A. Castrillo, D.C. Wilpitz, D.J. Mangelsdorf, J.L. Collins, E. Saez, P. Tontonoz, Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 100(9), 5419–5424 (2003). https://doi.org/10.1073/pnas.0830671100 CrossRefPubMedPubMedCentral

12.

G. Cao, Y. Liang, C.L. Broderick, B.A. Oldham, T.P. Beyer, R.J. Schmidt, Y. Zhang, K.R. Stayrook, C. Suen, K.A. Otto, A.R. Miller, J. Dai, P. Foxworthy, H. Gao, T.P. Ryan, X.C. Jiang, T.P. Burris, P.I. Eacho, G.J. Etgen, Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278(2), 1131–1136 (2003). https://doi.org/10.1074/jbc.M210208200 CrossRefPubMed

13.

Z.X. Meng, Y. Yin, J.H. Lv, M. Sha, Y. Lin, L. Gao, Y.X. Zhu, Y.J. Sun, X. Han, Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines. Diabetologia 55(6), 1733–1744 (2012). https://doi.org/10.1007/s00125-012-2516-2 CrossRefPubMed

14.

I. Gerin, V.W. Dolinsky, J.G. Shackman, R.T. Kennedy, S.H. Chiang, C.F. Burant, K.R. Steffensen, J.A. Gustafsson, O.A. MacDougald, LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J. Biol. Chem. 280(24), 23024–23031 (2005). https://doi.org/10.1074/jbc.M412564200 CrossRefPubMed

15.

H. Scholz, T. Lund, M.K. Dahle, J.L. Collins, O. Korsgren, J.E. Wang, A. Foss, The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro. Diabetologia 52(7), 1352–1362 (2009). https://doi.org/10.1007/s00125-009-1366-z CrossRefPubMed

16.

K.H. Hellemans, J.C. Hannaert, B. Denys, K.R. Steffensen, C. Raemdonck, G.A. Martens, P.P. Van Veldhoven, J.A. Gustafsson, D. Pipeleers, Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase. PLoS ONE 4(9), e7266 (2009). https://doi.org/10.1371/journal.pone.0007266 CrossRefPubMedPubMedCentral

17.

T. Ogihara, J.C. Chuang, G.L. Vestermark, J.C. Garmey, R.J. Ketchum, X. Huang, K.L. Brayman, M.O. Thorner, J.J. Repa, R.G. Mirmira, C. Evans-Molina, Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J. Biol. Chem. 285(8), 5392–5404 (2010). https://doi.org/10.1074/jbc.M109.064659 CrossRefPubMed

18.

A.M. Efanov, S. Sewing, K. Bokvist, J. Gromada, Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53(Suppl 3), S75–S78 (2004)CrossRefPubMed

19.

J. Maczewsky, J. Sikimic, C. Bauer, P. Krippeit-Drews, C. Wolke, U. Lendeckel, W. Barthlen, G. Drews, The LXR ligand T0901317 acutely inhibits insulin secretion by affecting mitochondrial metabolism. Endocrinology 158(7), 2145–2154 (2017). https://doi.org/10.1210/en.2016-1941 CrossRefPubMed

20.

B. Gier, P. Krippeit-Drews, T. Sheiko, L. Aguilar-Bryan, J. Bryan, M. Düfer, G. Drews,, Suppression of K_ATP channel activity protects murine pancreatic beta cells against oxidative stress. J. Clin. Investig. 119(11), 3246–3256 (2009). https://doi.org/10.1172/JCI38817 CrossRefPubMedPubMedCentral

21.

S. Alberti, G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. Angelin, I. Bjorkhem, S. Pettersson, J.A. Gustafsson, Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Investig. 107(5), 565–573 (2001). https://doi.org/10.1172/JCI9794 CrossRefPubMedPubMedCentral

22.

A. Edalat, P. Schulte-Mecklenbeck, C. Bauer, S. Undank, P. Krippeit-Drews, G. Drews, M. Düfer, Mitochondrial succinate dehydrogenase is involved in stimulus-secretion coupling and endogenous ROS formation in murine beta cells. Diabetologia 58(7), 1532–1541 (2015). https://doi.org/10.1007/s00125-015-3577-9 CrossRefPubMed

23.

M. Spyridon, L.A. Moraes, C.I. Jones, T. Sage, P. Sasikumar, G. Bucci, J.M. Gibbins, LXR as a novel antithrombotic target. Blood 117(21), 5751–5761 (2011). https://doi.org/10.1182/blood-2010-09-306142 CrossRefPubMedPubMedCentral

24.

A.J. Unsworth, A.P. Bye, D.S. Tannetta, M.J.R. Desborough, N. Kriek, T. Sage, H.E. Allan, M. Crescente, P. Yaqoob, T.D. Warner, C.I. Jones, J.M. Gibbins, Farnesoid X receptor and liver X receptor ligands initiate formation of coated platelets. Arterioscler. Thromb. Vasc. Biol. 37(8), 1482–1493 (2017). https://doi.org/10.1161/ATVBAHA.117.309135 CrossRefPubMedPubMedCentral

25.

S. Schaffer, R. Tandon, H. Zipse, W. Siess, A. Schmidt, J. Jamasbi, E. Karshovska, W. Steglich, R. Lorenz, Stereo specific platelet inhibition by the natural LXR agonist 22(R)-OH-cholesterol and its fluorescence labelling with preserved bioactivity and chiral handling in macrophages. Biochem. Pharm. 86(2), 279–285 (2013). https://doi.org/10.1016/j.bcp.2013.04.024 CrossRefPubMed

26.

V. Derangere, A. Chevriaux, F. Courtaut, M. Bruchard, H. Berger, F. Chalmin, S.Z. Causse, E. Limagne, F. Vegran, S. Ladoire, B. Simon, W. Boireau, A. Hichami, L. Apetoh, G. Mignot, F. Ghiringhelli, C. Rebe, Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ. 21(12), 1914–1924 (2014). https://doi.org/10.1038/cdd.2014.117 CrossRefPubMedPubMedCentral

27.

C. Rebe, V. Derangere, F. Ghiringhelli, Induction of pyroptosis in colon cancer cells by LXRbeta. Mol. Cell Oncol. 2(1), e970094 (2015). https://doi.org/10.4161/23723548.2014.970094 CrossRefPubMedPubMedCentral

28.

A.B. Ropero, B. Soria, A. Nadal, A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. Mol. Endocrinol. 16(3), 497–505 (2002)CrossRefPubMed

29.

S. Soriano, A.B. Ropero, P. Alonso-Magdalena, C. Ripoll, I. Quesada, B. Gassner, M. Kuhn, J.A. Gustafsson, A. Nadal, Rapid regulation of K(ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor. Mol. Endocrinol. 23(12), 1973–1982 (2009). https://doi.org/10.1210/me.2009-0287

30.

C.M. Revankar, D.F. Cimino, L.A. Sklar, J.B. Arterburn, E.R. Prossnitz, A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307(5715), 1625–1630 (2005)CrossRefPubMed

31.

W.P. Wong, J.P. Tiano, S. Liu, S.C. Hewitt, C. Le May, S. Dalle, J.A. Katzenellenbogen, B.S. Katzenellenbogen, K.S. Korach, F. Mauvais-Jarvis, Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc. Natl. Acad. Sci. 107(29), 13057–13062 (2010)

32.

E.R. Levin, S.R. Hammes, Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nat. Rev. Mol. Cell Biol. 17(12), 783–797 (2016). https://doi.org/10.1038/nrm.2016.122 CrossRefPubMedPubMedCentral

33.

S. Ackermann, S. Hiller, H. Osswald, M. Lösle, A. Grenz, A. Hambrock, 17β-Estradiol modulates apoptosis in pancreatic β-cells by specific involvement of the sulfonylurea receptor (SUR) isoform SUR1. J. Biol. Chem. 284(8), 4905–4913 (2009)CrossRefPubMed

34.

M. Düfer, K. Hörth, R. Wagner, B. Schittenhelm, S. Prowald, T.F. Wagner, J. Oberwinkler, R. Lukowski, F.J. Gonzalez, P. Krippeit-Drews, G. Drews, Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 61(6), 1479–1489 (2012). https://doi.org/10.2337/db11-0815 CrossRefPubMedPubMedCentral

35.

B. Schittenhelm, R. Wagner, V. Kähny, A. Peter, P. Krippeit-Drews, M. Düfer, G. Drews, Role of FXR in beta-Cells of Lean and Obese Mice. Endocrinology 156(4), 1263–1271 (2015). https://doi.org/10.1210/en.2014-1751 CrossRefPubMed

36.

H. Zitzer, W. Wente, M.B. Brenner, S. Sewing, K. Buschard, J. Gromada, A.M. Efanov, Sterol regulatory element-binding protein 1 mediates liver X receptor-beta-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. Endocrinology 147(8), 3898–3905 (2006). https://doi.org/10.1210/en.2005-1483 CrossRefPubMed

37.

M.F. Tavazoie, I. Pollack, R. Tanqueco, B.N. Ostendorf, B.S. Reis, F.C. Gonsalves, I. Kurth, C. Andreu-Agullo, M.L. Derbyshire, J. Posada, S. Takeda, K.N. Tafreshian, E. Rowinsky, M. Szarek, R.J. Waltzman, E.A. McMillan, C. Zhao, M. Mita, A. Mita, B. Chmielowski, M.A. Postow, A. Ribas, D. Mucida, S.F. Tavazoie, LXR/ApoE activation restricts innate immune suppression in cancer. Cell 172(4), 825–840 e818 (2018). https://doi.org/10.1016/j.cell.2017.12.026 CrossRefPubMedPubMedCentral

38.

T.G. Kirchgessner, P. Sleph, J. Ostrowski, J. Lupisella, C.S. Ryan, X. Liu, G. Fernando, D. Grimm, P. Shipkova, R. Zhang, R. Garcia, J. Zhu, A. He, H. Malone, R. Martin, K. Behnia, Z. Wang, Y.C. Barrett, R.J. Garmise, L. Yuan, J. Zhang, M.D. Gandhi, P. Wastall, T. Li, S. Du, L. Salvador, R. Mohan, G.H. Cantor, E. Kick, J. Lee, R.J. Frost, Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils. Cell Metab. 24(2), 223–233 (2016). https://doi.org/10.1016/j.cmet.2016.07.016 CrossRefPubMed

39.

A. Katz, C. Udata, E. Ott, L. Hickey, M.E. Burczynski, P. Burghart, O. Vesterqvist, X. Meng, Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharm. 49(6), 643–649 (2009). https://doi.org/10.1177/0091270009335768 CrossRef

Title: Approved LXR agonists exert unspecific effects on pancreatic β-cell function
Authors: Jonas Maczewsky
Julia Kaiser
Peter Krippeit-Drews
Gisela Drews
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Insulins
Insulins
Published in: Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02241-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study

Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up

Thyroid disease in the time of COVID-19

Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women

Mild TPO deficiency characterized by progressive goiter and normal serum TSH level

Atrophy patterns of hippocampal subfields in T2DM patients with cognitive impairment

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage